Logo image of VRDN

VIRIDIAN THERAPEUTICS INC (VRDN) Stock Fundamental Analysis

USA - NASDAQ:VRDN - US92790C1045 - Common Stock

18.62 USD
-0.04 (-0.21%)
Last: 9/17/2025, 5:20:02 PM
18.62 USD
0 (0%)
After Hours: 9/17/2025, 5:20:02 PM
Fundamental Rating

3

Overall VRDN gets a fundamental rating of 3 out of 10. We evaluated VRDN against 540 industry peers in the Biotechnology industry. The financial health of VRDN is average, but there are quite some concerns on its profitability. VRDN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VRDN has reported negative net income.
VRDN had a negative operating cash flow in the past year.
VRDN had negative earnings in each of the past 5 years.
VRDN had a negative operating cash flow in each of the past 5 years.
VRDN Yearly Net Income VS EBIT VS OCF VS FCFVRDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -59.08%, VRDN is in line with its industry, outperforming 44.07% of the companies in the same industry.
The Return On Equity of VRDN (-66.79%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -59.08%
ROE -66.79%
ROIC N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
VRDN Yearly ROA, ROE, ROICVRDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VRDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRDN Yearly Profit, Operating, Gross MarginsVRDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

VRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VRDN has been increased compared to 1 year ago.
The number of shares outstanding for VRDN has been increased compared to 5 years ago.
The debt/assets ratio for VRDN has been reduced compared to a year ago.
VRDN Yearly Shares OutstandingVRDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRDN Yearly Total Debt VS Total AssetsVRDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 9.75 indicates that VRDN is not in any danger for bankruptcy at the moment.
VRDN's Altman-Z score of 9.75 is amongst the best of the industry. VRDN outperforms 85.37% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that VRDN is not too dependend on debt financing.
VRDN has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: VRDN outperforms 41.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 9.75
ROIC/WACCN/A
WACC9.59%
VRDN Yearly LT Debt VS Equity VS FCFVRDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

VRDN has a Current Ratio of 11.01. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
VRDN's Current ratio of 11.01 is amongst the best of the industry. VRDN outperforms 82.96% of its industry peers.
VRDN has a Quick Ratio of 11.01. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 11.01, VRDN belongs to the best of the industry, outperforming 82.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.01
Quick Ratio 11.01
VRDN Yearly Current Assets VS Current LiabilitesVRDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

VRDN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.41%.
The Revenue has been growing slightly by 6.64% in the past year.
The Revenue for VRDN have been decreasing by -41.64% on average. This is quite bad
EPS 1Y (TTM)5.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
Revenue 1Y (TTM)6.64%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%4.17%

3.2 Future

The Earnings Per Share is expected to grow by 22.18% on average over the next years. This is a very strong growth
Based on estimates for the next years, VRDN will show a very strong growth in Revenue. The Revenue will grow by 400.17% on average per year.
EPS Next Y1.54%
EPS Next 2Y-3.16%
EPS Next 3Y14.85%
EPS Next 5Y22.18%
Revenue Next Year-52.85%
Revenue Next 2Y1169.46%
Revenue Next 3Y864.85%
Revenue Next 5Y400.17%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VRDN Yearly Revenue VS EstimatesVRDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
VRDN Yearly EPS VS EstimatesVRDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VRDN. In the last year negative earnings were reported.
Also next year VRDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRDN Price Earnings VS Forward Price EarningsVRDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRDN Per share dataVRDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as VRDN's earnings are expected to grow with 14.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.16%
EPS Next 3Y14.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRDN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRIDIAN THERAPEUTICS INC

NASDAQ:VRDN (9/17/2025, 5:20:02 PM)

After market: 18.62 0 (0%)

18.62

-0.04 (-0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-10 2025-11-10/amc
Inst Owners113.92%
Inst Owner Change2.8%
Ins Owners0.04%
Ins Owner Change0%
Market Cap1.52B
Analysts85.22
Price Target39.4 (111.6%)
Short Float %14.27%
Short Ratio14.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.34%
Min EPS beat(2)2.88%
Max EPS beat(2)11.8%
EPS beat(4)3
Avg EPS beat(4)3.35%
Min EPS beat(4)-6.6%
Max EPS beat(4)11.8%
EPS beat(8)5
Avg EPS beat(8)1.79%
EPS beat(12)7
Avg EPS beat(12)-5.98%
EPS beat(16)9
Avg EPS beat(16)-6.46%
Revenue beat(2)2
Avg Revenue beat(2)34.57%
Min Revenue beat(2)0.65%
Max Revenue beat(2)68.49%
Revenue beat(4)4
Avg Revenue beat(4)53%
Min Revenue beat(4)0.65%
Max Revenue beat(4)84.21%
Revenue beat(8)4
Avg Revenue beat(8)12.64%
Revenue beat(12)5
Avg Revenue beat(12)18.46%
Revenue beat(16)6
Avg Revenue beat(16)7.49%
PT rev (1m)-1.9%
PT rev (3m)-1.9%
EPS NQ rev (1m)-11.02%
EPS NQ rev (3m)0.53%
EPS NY rev (1m)3.29%
EPS NY rev (3m)3.49%
Revenue NQ rev (1m)-17.21%
Revenue NQ rev (3m)-7.72%
Revenue NY rev (1m)-24.95%
Revenue NY rev (3m)-24.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4985.28
P/FCF N/A
P/OCF N/A
P/B 2.95
P/tB 2.95
EV/EBITDA N/A
EPS(TTM)-4.02
EYN/A
EPS(NY)-4.21
Fwd EYN/A
FCF(TTM)-3.79
FCFYN/A
OCF(TTM)-3.78
OCFYN/A
SpS0
BVpS6.31
TBVpS6.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.08%
ROE -66.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 110.77%
Cap/Sales 175.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.01
Quick Ratio 11.01
Altman-Z 9.75
F-Score3
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)191.45%
Cap/Depr(5y)174.87%
Cap/Sales(3y)166.8%
Cap/Sales(5y)103.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
EPS Next Y1.54%
EPS Next 2Y-3.16%
EPS Next 3Y14.85%
EPS Next 5Y22.18%
Revenue 1Y (TTM)6.64%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%4.17%
Revenue Next Year-52.85%
Revenue Next 2Y1169.46%
Revenue Next 3Y864.85%
Revenue Next 5Y400.17%
EBIT growth 1Y-48.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.93%
EBIT Next 3Y11.83%
EBIT Next 5Y36.92%
FCF growth 1Y-90.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-90.9%
OCF growth 3YN/A
OCF growth 5YN/A